Lessons learned from clinical trials in SLE-Reference-Cited by-同舟云学术

Lessons learned from clinical trials in SLE

Published:2007-03 Issue:4 Volume:6 Page:209-214
ISSN:1568-9972
Container-title:Autoimmunity Reviews
language:en
Short-container-title:Autoimmunity Reviews

Author:

Strand Vibeke

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference37 articles.

1. Outcome measures to be used in clinical trials in systemic lupus erythematosus;Strand;J Rheumatol,1999

2. Randomized clinical trials and longitudinal observational studies in SLE: consensus on a preliminary core set of outcome domains;Smolen;J Rheumatol,1999

3. Issues in Drug Development in SLE: Clinical Trial Design, Outcome Measures and Biomarkers;Strand,2006

4. Definition and treatment of lupus flares measured by the BILAG index;Gordon;Rheumatology,2003

5. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus;Ward;J Rheumatol,2000

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index;Arthritis Care & Research;2021-07-27

2. Serum interleukin-18 and interleukin-10 levels in systemic lupus erythematosus: correlation with SLEDAI score and disease activity parameters;Egyptian Rheumatology and Rehabilitation;2014-10

3. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006;Rheumatology;2013-11-22

4. The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey;Rheumatology;2013-09-18

5. Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study;Arthritis & Rheumatism;2013-03-28